Compare COHU & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHU | HRMY |
|---|---|---|
| Founded | 1947 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 1994 | 2020 |
| Metric | COHU | HRMY |
|---|---|---|
| Price | $47.68 | $36.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $40.50 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 1.0M | 856.6K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 0.55 |
| Revenue | $452,956,000.00 | ★ $868,453,000.00 |
| Revenue This Year | $14.38 | $19.75 |
| Revenue Next Year | $19.12 | $12.88 |
| P/E Ratio | ★ N/A | $65.47 |
| Revenue Growth | 12.74 | ★ 21.51 |
| 52 Week Low | $17.80 | $25.52 |
| 52 Week High | $74.60 | $40.87 |
| Indicator | COHU | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 53.78 |
| Support Level | $43.64 | $35.05 |
| Resistance Level | $52.43 | $39.07 |
| Average True Range (ATR) | 3.54 | 1.56 |
| MACD | -0.88 | -0.14 |
| Stochastic Oscillator | 6.42 | 58.35 |
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads, and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection). Geographically, the company generates maximum revenue from the Philippines, followed by Taiwan, China, Malaysia, the United States, Singapore, and the Rest of the world.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.